Sir Chris Hoy has launched a major initiative aiming to screen 25,000 men across Scotland for prostate cancer, channelling his own incurable diagnosis into a urgent public health mission.
The Scottish Prostate Cancer Initiative, launched in Glasgow, will offer free PSA blood tests to men aged between 40 and 80 throughout the year, with the goal of improving early detection rates. The project is being delivered by Professor Sir Chris Evans’s company, EDX Medical Group, and its findings will be made available to NHS Scotland to explore how clinical pathways for the disease can be improved.
A New Purpose Driven by Personal Pain
The drive behind the project is profoundly personal. Sir Chris Hoy, one of Britain’s most decorated Olympians, announced in October 2024 that he had been diagnosed with incurable, stage four prostate cancer which had spread to his bones, and had been given between two and four years to live. He described the news as “devastating”.
“A stage four diagnosis changes your life drastically but I guess it’s finding a new purpose,” Sir Chris said, “and today’s event is all about trying to educate men about the importance of catching prostate cancer early.” He revealed he was diagnosed in September 2023, and has since been open about the impact, stating that this new purpose now defines his focus.
He also shared a stark personal lesson about the disease’s unpredictability. “I always assumed there would be some kind of symptoms or early-warning signs… we’re always told it’s 50 years and above, that it’s an older man’s disease, and it’s slow-moving, and you’ll get warning signs. That’s not always the case.”
The Critical Case for Early Detection
The initiative addresses a dire health disparity within the UK. Sir Chris highlighted that around 35% of men in Scotland with prostate cancer are diagnosed when it is too late to be cured, compared to just 12.5% in London. He stated that men born in Scotland are three times more likely to receive a stage four incurable diagnosis.
These figures are underscored by national statistics: prostate cancer is the most common cancer among men in Scotland, with approximately one in ten diagnosed. In 2022 alone, there were over 5,000 new cases, with almost a third (31%) diagnosed too late for a cure—the highest rate in the UK.
Professor Sir Chris Evans emphasised the human and economic imperative for early action. He explained that treating stage one, curable prostate cancer costs thousands of pounds, while managing terminal stage four disease can cost hundreds of thousands per year, with cumulative costs for advanced cases potentially exceeding half a million pounds per person.
Demystifying the PSA Test and the Screening Debate
At the heart of the initiative is the PSA (prostate-specific antigen) blood test. Sir Chris’s central message to men is straightforward: “It’s just a simple blood test… You’re in and out of the doctor’s in five minutes. It’s easy, it’s simple, it’s painless – and it could save your life.”
However, the test exists within a complex medical debate. The UK National Screening Committee (UK NSC) does not currently recommend a national population screening programme, citing concerns that the harms of PSA testing—such as false positives, overdiagnosis of slow-growing cancers, and unnecessary invasive procedures—can outweigh the benefits.
Despite this, emerging evidence is shifting the conversation. A landmark European study, published in the New England Journal of Medicine, concluded that regular PSA screening can reduce prostate cancer deaths by 13%, with one death prevented for every 456 men invited. In light of such data, the Scottish Government has urged the UK NSC to review the case for a national programme.
The UK NSC is currently consulting on a draft recommendation to offer targeted screening every two years to men aged 45-61 with confirmed BRCA1 or BRCA2 gene variants. It does not, however, currently advocate targeted screening for Black men or those with a family history based on present evidence. Prostate Cancer UK recommends that these higher-risk groups speak to their GP about a PSA test from age 45.
To address the limitations of the standard PSA test, Professor Evans’s EDX Medical Group has developed an advanced “super test” using a multi-omics approach. This non-invasive test analyses over 100 biomarkers from blood and urine with AI, aiming for 96-99% accuracy in detecting cancer cells, determining stage, and predicting prognosis.
The new Scottish initiative is a practical step that exists alongside wider UK research, such as the TRANSFORM trial, which is comparing screening methods including genetic analysis and MRI scans. Men in Scotland can now book a free test via the project’s website, www.scottishprostate.com.
Sir Chris is joined in his advocacy by other high-profile figures, including former Scotland rugby international Kenny Logan, who was diagnosed in 2022 and credits a routine check with saving his life. Their collective aim is clear: to turn the tide on late diagnosis and provide a model that could reshape national policy.